跳至主要内容
临床试验/JPRN-UMIN000002444
JPRN-UMIN000002444招募中未知

Randomized study of anti-coagulant therapy to preventpostoperative deep venous thrombosis/pulmonary embolism - Randomized study of anti-coagulant therapy to preventpostoperative deep venous thrombosis/pulmonary embolism

unversity of tokushima, surgery0 个研究点目标入组 300 人开始时间: 2009年10月1日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 未提供

研究者

发起方
unversity of tokushima, surgery

相似试验

已完成
不适用
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate-I48 Atrial fibrillation and flutterAtrial fibrillation and flutterI48
PER-087-06BOEHRINGER INGELHEIM PHARMA,
进行中(未招募)
不适用
Randomized evaluation of long term anticoagulant therapy (RELY)comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non inferiority trial (RELY STUDY) - RELYprevention of stroke and systemic embolism in patients with non-valvular atrial fibrillationMedDRA version: 14.1Level: HLTClassification code 10000032Term: Cardiac conduction disordersSystem Organ Class: 100000004849
EUCTR2005-003894-26-ITBOEHRINGER ING.15,000
进行中(未招募)
不适用
Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY) - RE-LYPrevention of Stroke and Systemic Embolism in patients with Atrial Fibrillation
EUCTR2005-003894-26-PTBoehringer Ingelheim Pharma GmbH & Co. KG15,000
进行中(未招募)
1 期
Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY) - RE-LY
EUCTR2005-003894-26-GBBoehringer Ingelheim Ltd.18,000
进行中(未招募)
不适用
Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY) - RE-LYPrevention of Stroke and Systemic Embolism in patients with Atrial Fibrillation
EUCTR2005-003894-26-DKBoehringer Ingelheim Pharma GmbH & Co KG18,000